mycophenolate mofetil

(redirected from Cellcept)
Also found in: Medical.
Translations

mycophenolate mofetil

n micofenolato de mofetilo
References in periodicals archive ?
James and her OMRF research staff focused on an immunosuppressive drug called mycophenolate mofetil (CellCept or MMF), developed for people who have had kidney, heart or liver transplants.
All of the other treatments she uses for juvenile localized scleroderma - mycophenolate mofetil (CellCept), abatacept (Orencia), tocilizumab (Actemra), and occasionally others--are backed only by a smattering of small case series.
It is important to note that CellCept has not been approved by the FDA for the treatment of any autoimmune disease.
He has had success in a single patient with mycophenolate mofetil (CellCept), the steroid-sparing immunosuppressant.
Two examples already available are Rapamune and CellCept, while others are still in the research pipeline.
Results from an on-going trial of CellCept were presented at the American Transplant Congress in Washington DC lastnight.
The day before surgery, you receive large amounts of Prednisone, an anti-inflammatory drug, as well as the immunosuppressants Prograf and Cellcept. Antiviral, antifungal, and antibacterial drugs help the immune system fight off infection.
WHAT CELLCEPT (mycophenolate mofetil), a drug that prevents rejection of transplants, for secondary-progressive MS WHERE At 2 sites in the U.S.
Patients were randomly assigned treatment with a combination of either the immunosuppressants cyclosporine, prednisone, CellCept (mycophenolate mofetil), and Zenapax, or cyclosporine, prednisone, and CellCept alone.
The AURORA study is a 52-week global double-blind placebo controlled Phase 3 study that will compare the efficacy of one dose of voclosporin (23.7mg BID) to placebo when added to current standard of care of mycophenolate mofetil (MMF, also known as CellCept) in achieving renal response (formerly referred to as complete remission) in patients with active LN.
Mycophenolate acid (MFA) is available in 2 forms: mycophenolate mofetil (MMF; CellCept, Roche, Nutley, New Jersey) and mycophenolate sodium (Myfortic, Novartis, East Hanover, New Jersey).
Refractory patients received a wide range of systemic agents--most commonly chloroquine (Aralen) and mycophenolate mofetil (Cellcept), followed by quinacrine, dapsone, methotrexate, belimumab (Benlysta), azathioprine, thalidomide (Thalomid), lenalidomide (Revlimid), prednisone, and rituximab (Rituxan), Ms.